In a new study of CAR T-cell therapy for cancer, 93% of patients responded to the treatment.
Two physicians had major roles in a cutting-edge clinical trial using the body’s own immune cells to fight late-stage cancer, one as a researcher and one as a patient.
Senior author Patrick Reagan, an assistant professor of hematology/oncology at University of Rochester Medicine’s Wilmot Cancer Institute, helped run the national clinical investigation of CAR T-cell therapy.
Continue reading… “93% of cancer patients respond to souped-up-immune cells”
